Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective,...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2021-11-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2021.1984644 |
| _version_ | 1797972793380306944 |
|---|---|
| author | Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee |
| author_facet | Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee |
| author_sort | Abuzar A. Asif |
| collection | DOAJ |
| description | Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19. |
| first_indexed | 2024-04-11T03:54:02Z |
| format | Article |
| id | doaj.art-543ed69dc9d34b20a702f2a6015eb96c |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T03:54:02Z |
| publishDate | 2021-11-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-543ed69dc9d34b20a702f2a6015eb96c2023-01-02T01:11:25ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662021-11-0111676076810.1080/20009666.2021.19846441984644Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic reviewAbuzar A. Asif0Habiba Hussain1Sriviji Senthil Kumaran2Salman B. Syed3Varun Vanka4Manisha Tharoor5Umme Salma Rangwala6Urvashi Rathore7Malay Singhal8Tulika Chatterjee9University of Illinois College of MedicineUniversity of Illinois College of MedicineUniversity of Illinois College of MedicineUniversity of Illinois College of MedicineUniversity of Illinois College of MedicineUniversity of Illinois College of MedicineMahatma Gandhi Memorial Medical CollegeMahatma Gandhi Memorial Medical CollegeMahatma Gandhi Memorial Medical CollegeUniversity of Illinois College of MedicineType 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19.http://dx.doi.org/10.1080/20009666.2021.1984644interferon-betacovid-19coronavirusmeta-analysissystematic reviewpandemicefficacysubcutaneous |
| spellingShingle | Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review Journal of Community Hospital Internal Medicine Perspectives interferon-beta covid-19 coronavirus meta-analysis systematic review pandemic efficacy subcutaneous |
| title | Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review |
| title_full | Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review |
| title_fullStr | Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review |
| title_full_unstemmed | Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review |
| title_short | Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review |
| title_sort | efficacy of subcutaneous interferon beta in covid 19 a meta analysis and systematic review |
| topic | interferon-beta covid-19 coronavirus meta-analysis systematic review pandemic efficacy subcutaneous |
| url | http://dx.doi.org/10.1080/20009666.2021.1984644 |
| work_keys_str_mv | AT abuzaraasif efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT habibahussain efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT srivijisenthilkumaran efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT salmanbsyed efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT varunvanka efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT manishatharoor efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT ummesalmarangwala efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT urvashirathore efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT malaysinghal efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT tulikachatterjee efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview |